Factor XIII: inherited and acquired deficiency

Area of Science:

• Biochemistry
• Haematology
• Molecular Biology

Background:

• Factor XIII (FXIII) is a plasma enzyme vital for normal hemostasis and potentially wound healing.
• Inherited FXIII deficiency leads to severe bleeding, with a high risk of fatal intracranial hemorrhage.
• FXIII functions as a zymogen, activated by thrombin and calcium, crosslinking fibrin and other proteins to stabilize clots.

Purpose of the Study:

• To review the role of Factor XIII in hemostasis, wound healing, and its clinical implications.
• To discuss the molecular basis of inherited FXIII deficiency and treatment strategies.
• To explore acquired FXIII deficiency and the use of FXIII therapy in various conditions.

Main Methods:

• Literature review of Factor XIII's function, deficiency states, and therapeutic applications.
• Analysis of molecular defects in inherited FXIII deficiency.
• Examination of clinical outcomes for FXIII replacement therapy.

Main Results:

• Inherited FXIII deficiency, often caused by single point mutations, results in severe bleeding diathesis.
• Prophylaxis with Factor XIII is effective due to its long in vivo half-life and sufficiency of low plasma levels.
• Acquired FXIII deficiency can occur in various diseases, with therapy showing variable success; its use in wound healing is controversial.

Conclusions:

• Factor XIII is indispensable for hemostasis, and its deficiency necessitates timely intervention.
• Effective management strategies exist for inherited FXIII deficiency, including prophylaxis.
• The role of Factor XIII in acquired conditions and wound healing requires further investigation.